Twitter Facebook LinkedIn WhatsApp Press Releases Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 (-) 2013 2012 2011 2010 2009 Reset 2013 December 16, 2013 ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study November 3, 2013 arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer November 3, 2013 arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B September 18, 2013 arGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire September 16, 2013 arGEN-X initiates Phase Ib study of ARGX-111 in cancer September 11, 2013 arGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7 August 5, 2013 arGEN-X grants license to its NHance™ antibody half-life extension technology April 25, 2013 arGEN-X to Present at Upcoming Ninth Annual PEGS 2013 March 24, 2013 arGEN-X announces preclinical development of ARGX-112 for dermatology January 6, 2013 arGEN-X initiates Phase Ib study of ARGX-110 in cancer January 6, 2013 arGEN-X expands its therapeutic antibody alliance with Shire
